Format

Send to

Choose Destination
Nat Rev Drug Discov. 2013 Jul;12(7):507-25.

Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease.

Author information

1
Department of Neurology and Neurological Sciences, Stanford University, 300 Pasteur Drive, Stanford, California 94305, USA. longo@stanford.edu

Abstract

Neurotrophins and their receptors modulate multiple signalling pathways to regulate neuronal survival and to maintain axonal and dendritic networks and synaptic plasticity. Neurotrophins have potential for the treatment of neurological diseases. However, their therapeutic application has been limited owing to their poor plasma stability, restricted nervous system penetration and, importantly, the pleiotropic actions that derive from their concomitant binding to multiple receptors. One strategy to overcome these limitations is to target individual neurotrophin receptors — such as tropomyosin receptor kinase A (TRKA), TRKB, TRKC, the p75 neurotrophin receptor or sortilin — with small-molecule ligands. Such small molecules might also modulate various aspects of these signalling pathways in ways that are distinct from the programmes triggered by native neurotrophins. By departing from conventional neurotrophin signalling, these ligands might provide novel therapeutic options for a broad range of neurological indications.

PMID:
23977697
DOI:
10.1038/nrd4024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center